Cher Y Enderby1, Charles Burger2. 1. Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. 2. Mayo Clinic, Jacksonville, FL, USA.
Abstract
BACKGROUND: Treprostinil is a prostacyclin analogue that directly vasodilates pulmonary and systemic arterial vascular beds. The United States Food and Drug Administration approved inhaled treprostinil in July 2009 for the treatment of group 1 pulmonary arterial hypertension. Inhaled treprostinil avoids issues with continuous infusion prostanoids. This study describes a single institutional experience with inhaled treprostinil. METHODS: This was a retrospective review of group 1 pulmonary arterial hypertension patients receiving inhaled treprostinil from July 2009 through September 2015. Patient demographics, vital signs, prognostic indicators, pulmonary arterial hypertension assessments, treprostinil dosing, pulmonary arterial hypertension medications, and physician assessment were collected. Prognostic indicators and the physician assessment were used to assess treatment response. A modified Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) risk score was calculated prior to and after initiation of inhaled treprostinil. RESULTS: The mean time on inhaled treprostinil for the 16 patients was 21 ± 17 months. A total of 31% discontinued treatment. The New York Heart Association Functional Class, right ventricular size, and right ventricular function improved after inhaled treprostinil. Directional improvement in B-type natriuretic peptide, 6-minute walk distance, right arterial pressure and mean pulmonary artery pressure were also observed. The mean modified REVEAL risk score (RRS) was 7 ± 3 at baseline. The RRS decreased in 7 of the 11 patients that improved and remained stable in 2 patients. CONCLUSION: The majority of patients in this consecutive series receiving inhaled treprostinil tolerated treatment. Most patients remained on therapy for over 12 months. Clinical assessments of disease severity all changed directionally toward improvement and the overall risk assessment was improved or stable in 56% by the RRS.
BACKGROUND: Treprostinil is a prostacyclin analogue that directly vasodilates pulmonary and systemic arterial vascular beds. The United States Food and Drug Administration approved inhaled treprostinil in July 2009 for the treatment of group 1 pulmonary arterial hypertension. Inhaled treprostinil avoids issues with continuous infusion prostanoids. This study describes a single institutional experience with inhaled treprostinil. METHODS: This was a retrospective review of group 1 pulmonary arterial hypertension patients receiving inhaled treprostinil from July 2009 through September 2015. Patient demographics, vital signs, prognostic indicators, pulmonary arterial hypertension assessments, treprostinil dosing, pulmonary arterial hypertension medications, and physician assessment were collected. Prognostic indicators and the physician assessment were used to assess treatment response. A modified Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) risk score was calculated prior to and after initiation of inhaled treprostinil. RESULTS: The mean time on inhaled treprostinil for the 16 patients was 21 ± 17 months. A total of 31% discontinued treatment. The New York Heart Association Functional Class, right ventricular size, and right ventricular function improved after inhaled treprostinil. Directional improvement in B-type natriuretic peptide, 6-minute walk distance, right arterial pressure and mean pulmonary artery pressure were also observed. The mean modified REVEAL risk score (RRS) was 7 ± 3 at baseline. The RRS decreased in 7 of the 11 patients that improved and remained stable in 2 patients. CONCLUSION: The majority of patients in this consecutive series receiving inhaled treprostinil tolerated treatment. Most patients remained on therapy for over 12 months. Clinical assessments of disease severity all changed directionally toward improvement and the overall risk assessment was improved or stable in 56% by the RRS.
Authors: Garvan C Kane; Hilal Maradit-Kremers; Josh P Slusser; Chris G Scott; Robert P Frantz; Michael D McGoon Journal: Chest Date: 2010-11-11 Impact factor: 9.410
Authors: Michael D McGoon; Abby Krichman; Harrison W Farber; Robyn J Barst; Gary E Raskob; Theodore G Liou; Dave P Miller; Kathy Feldkircher; Scott Giles Journal: Mayo Clin Proc Date: 2008-08 Impact factor: 7.616
Authors: Richard N Channick; Horst Olschewski; Werner Seeger; Ted Staub; Robert Voswinckel; Lewis J Rubin Journal: J Am Coll Cardiol Date: 2006-09-14 Impact factor: 24.094
Authors: Vallerie V McLaughlin; Raymond L Benza; Lewis J Rubin; Richard N Channick; Robert Voswinckel; Victor F Tapson; Ivan M Robbins; Horst Olschewski; Melvyn Rubenfire; Werner Seeger Journal: J Am Coll Cardiol Date: 2010-05-04 Impact factor: 24.094
Authors: Robert Voswinckel; Beate Enke; Frank Reichenberger; Markus Kohstall; Andree Kreckel; Stefanie Krick; Henning Gall; Tobias Gessler; Thomas Schmehl; Hossein A Ghofrani; Ralph Theo Schermuly; Friedrich Grimminger; Lewis J Rubin; Werner Seeger; Horst Olschewski Journal: J Am Coll Cardiol Date: 2006-09-26 Impact factor: 24.094
Authors: H Olschewski; H A Ghofrani; D Walmrath; R Schermuly; B Temmesfeld-Wollbruck; F Grimminger; W Seeger Journal: Am J Respir Crit Care Med Date: 1999-08 Impact factor: 21.405
Authors: Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger Journal: N Engl J Med Date: 2002-08-01 Impact factor: 91.245
Authors: Hubert Chen; Erika B Rosenzweig; S Karl Gotzkowsky; Carl Arneson; Andrew C Nelsen; Robert C Bourge Journal: Health Qual Life Outcomes Date: 2013-03-06 Impact factor: 3.186